Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development
April 01 2020 - 7:00AM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today
announced that Dr. Gregory Stein has joined the Company as Senior
Vice President of Clinical Development.
Dr. Stein is a highly regarded founder and
executive of several healthcare and biotechnology companies. Most
recently he co-founded and served as Chief Executive Officer at
Curtana Pharmaceuticals, which develops drugs for the treatment of
glioblastoma and other brain cancers. Curtana was awarded funding
from the Cancer Prevention and Research Institute of Texas.
Prior to Curtana, Dr. Stein was also a founder and
served as the Vice President, Operations and Medical Affairs at
Sova Pharmaceuticals, Inc., a venture-backed company that developed
therapies for sleep-related breathing disorders and neuropathic
pain. In addition, Dr. Stein has held senior positions at Genoptix,
Opus Pharmaceuticals and Uzima Bioscience.
Dr. Stein was formerly a board-certified Emergency
Medicine Physician and previously practiced in Chicago, serving as
the Assistant Medical Director of the department and Associate
Emergency Medical Services Director for the regional EMS
system.
Dr. Stein is a graduate of the accelerated program
at the Ohio State University School of Medicine and completed his
residency at the University of Illinois Affiliated Hospitals in
Chicago. In addition, Dr. Stein has an MBA from The Rady School of
Management at UC San Diego.
"Dr. Gregory Stein is an accomplished physician
with a successful track record in drug development while in
industry,” said Dr. Marc Hedrick, President and CEO of Plus
Therapeutics. “Greg’s background, and in particular deep
knowledge in neuro-oncology, make him an ideal addition to our
world class team.” About Plus Therapeutics,
Inc.
Plus Therapeutics, Inc. is a clinical-stage
pharmaceutical company focused on the discovery, development, and
delivery of complex and innovative treatments for patients battling
cancer and rare diseases.
Our proprietary nanotechnology platform is
currently centered around the enhanced delivery of a variety of
drugs using novel liposomal encapsulation technology. Liposomal
encapsulation has been extensively explored and undergone
significant technical and commercial advances since it was first
developed. Our platform is designed to facilitate new delivery
approaches and/or formulations of safe and effective, injectable
drugs, potentially enhancing the safety, efficacy and convenience
for patients and healthcare providers.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains certain statements that
may be deemed “forward-looking statements” within the meaning of
U.S. securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop a market leading position; and the potential
for, and timing of, the Company’s submission of a Phase 2 clinical
trial protocol in Small Cell Lung Cancer patients with
platinum-sensitive disease who progressed at least 60 days after
initiation of first-line chemotherapy. The forward-looking
statements included in this press release are subject to a number
of additional material risks and uncertainties, including but not
limited to: the risk that the U.S. FDA does not accept the
Company’s submission of a Phase 2 clinical trial protocol in Small
Cell Lung Cancer patients with platinum-sensitive disease who
progressed at least 60 days after initiation of first-line
chemotherapy; the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Plus Therapeutics, Inc.
Andrew Sims CFO/VP, Investor Relations Phone: +1.619.333.4150
Email: ir@plustherapeutics.com
Website: plustherapeutics.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2023 to Apr 2024